Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Takeda Oncology.

Oncology Consultations®: Improving Patient Outcomes in Multiple Myeloma Across Lines of Care With Proteasome Inhibitors

Release Date: October 15, 2020
Expiration Date: October 15, 2021

Activity Overview

The Oncology Consultation™ is a video-based program in which 2 distinguished experts engage in a discussion on a particular clinical topic. In this activity, 2 hematology experts explore the role of proteasome inhibitors (PI) in the management of multiple myeloma (MM). Topics addressed include advances in treatment strategies, emerging therapies, management of toxicities, and the impact of disease-specific factors, treatment history, and risk stratification on PI-based treatment decisions. This lively discussion will help place new developments into clinical context to help you optimize care for your patients with MM.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Takeda Oncology.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists, hematologists, and other health care professionals interested in the treatment of hematologic malignancies.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Explain the impact of disease-specific factors, treatment history and risk stratification on PI-based treatment decisions in MM across lines of care.
  • Assess the efficacy and safety profile for current and emerging PI-based therapies in multiple lines of care among patients with MM
  • Determine treatment-related toxicities associated with PI-based therapeutic strategies in the context of approaches to maximize outcomes in MM
  • Apply evidence from landmark trials evaluating PI-based therapies in MM to real-world case scenarios in the management of patients with this disease

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Shaji Kumar, MD
Shaji Kumar, MD
Professor of Medicine
Consultant, Division of Hematology
Mayo Clinic
Rochester, MN

Disclosures: Grant/Research Support: Research funding for clinical trials to the institution: Celgene, Takeda Pharmaceutical Company, Janssen Pharmaceuticals, Bristol Myers Squibb, Kite Pharma, Merck & Co, AbbVie, MedImmune, Novartis, F. Hoffman-La Roche-Genentech, Amgen, TeneoBio, CARsgen Therapeutics; Consultant/Advisory Board: Celgene, Takeda Pharmaceutical Company, Janssen Pharmaceuticals, AbbVie, Genentech, Amgen, Molecular Partners and (with personal payment) Oncopeptides, GeneCentrix, Cellectar Biosciences.

Irene Ghobrial, MD
Irene Ghobrial, MD
Professor of Medicine
Director of the Center for Prevention of Progression
Director of the Clinical Investigator Program
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Consultant: GlaxoSmithKline, Sanofi, Janssen Pharmaceuticals, Takeda Pharmaceutical Company, Celgene, Karyopharm, AbbVie, GNS Healthcare, Cellectar Biosciences, Medscape, Genentech/F. Hoffman-La Roche, Adaptive Biotechnologies, Bristol Myers Squibb, Aptitude Medical Systems, Curio Biotech, Oncopeptides.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By